Dissemin is shutting down on January 1st, 2025

Published in

Bentham Science Publishers, Current Molecular Medicine, 3(12), p. 259-267

DOI: 10.2174/156652412799218903

Links

Tools

Export citation

Search in Google Scholar

The PD-1/PD-L1 Pathway in Human Pathology

Journal article published in 2012 by M. Saresella, V. Rainone, N. M. Al-Daghri, M. Clerici ORCID, D. Trabattoni
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

T-cell activation is dependent on signals delivered through the antigen-specific T-cell receptor and accessory receptors on T-cells. Integration of signals through this family of costimulatory and inhibitory receptors and their ligands regulates the balance between T-cell activation, tolerance, and immunopathology. Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2, deliver inhibitory signals and exert a vital and diverse range of immunoregulatory roles in T-cell activation, tolerance, and immune-mediated tissue damage. In this review, we revisit current understanding of the immunoregulatory functions of PD-1 and its ligands and their involvement in immune-mediated diseases.